Inscripta, Inc.

Inscripta, Inc.

Biotechnology Research

Pleasanton, California 12,926 followers

The Digital Genome Engineering Company

Über uns

Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California. To learn more, visit Inscripta.com and follow @InscriptaInc.

Website
https://www.inscripta.com/
Industrie
Biotechnology Research
Größe des Unternehmens
51-200 Mitarbeiter
Hauptsitz
Pleasanton, California
Typ
In Privatbesitz
Gegründet
2015
Spezialitäten
Digital Genome Engineering, Gene Editing, Synthetic Biology, Genome Editing, CRISPR, MAD7, MADzymes, Single Cell Writing, and Single-Cell Genomics

Standorte

Employees at Inscripta, Inc.

Aktualisierungen

  • View organization page for Inscripta, Inc. , graphic

    12,926 followers

    Thank you Roger Wyse for sharing this important call to action. Inscripta is fortunate to have you on our Board and we believe that now is the time for coordinated approaches to help make a significant impact to our bioeconomy. #bioeconomy #synbio #crispr

    View profile for Roger W., graphic

    Founder & Managing Partner at Spruce Capital Partners

    Building a Robust Bioeconomy The opportunity to build a robust bioeconomy has never been greater nor more urgently needed. The convergence of technologies, and market pull coupled with political support and government funding is a powerful foundation on which to address some of the most important challenges facing the world today: food security, energy security, climate change, sustainability, and national security. However todate the bio industry has been unable to deliver on its full potential. What must change? Supported by the Alternative Fuels and Chemicals Coalition (AFCC), I had the privilege of leading a group of industry veterans to consider: “What is needed to reduce the timeline to develop and commercialize products by at least half?”  The members were all passionate about the potential positive impact of biobased companies but concerned about the lack of financial success stories and the extended timelines to significant impact. The Concern and Call to Action Currently the time from discovery to significant market impact is 15 – 25 years. Too long to meet climate mitigation goals in the 2030 to 2050 timeframe; too long to sustain political support; too long to meet the ROI of investors. The conclusion of the study was that major changes will be needed to build a new globally optimized, massively scaled, highly efficient bio-based supply chain quickly enough to meet the challenges of climate change, food security, national security, and sustainability. The industry has had strong leadership and great technologies over the past 20 – 30 years but few successful companies. Missing is a conducive ecosystem that increases the probably of success. The development of the new ecosystem must be industry led. It will require adopting bold new ways of working along the entire value chain. Success will require a strong co-equal public-private partnership between industry and governments. Bold changes by industry must be matched by sustained supportive actions by government and vice versa. The report entitled “Building a Robust Bioeconomy: A Statement of Concern & Call to Action” was released at the AFCC conference last week to very positive reviews. A summary of the report follows and includes a link to the full report. We welcome your comments.

Ähnliche Seiten

Jobs durchsuchen

Finanzierung

Inscripta, Inc. 9 total rounds

Letzte Runde

Serie unbekannt

US$ 4.4M

Siehe mehr Informationen auf crunchbase